HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Tesaglitazar.

Abstract
AstraZeneca plc is developing tesaglitazar, an oral dual peroxisome proliferator-activated receptor alpha/gamma agonist, for the potential improvement of dyslipidemia and glycemic control in type 2 diabetic patients.
AuthorsNiklaus Kamber, Timothy M E Davis
JournalIDrugs : the investigational drugs journal (IDrugs) Vol. 8 Issue 11 Pg. 927-35 (Nov 2005) ISSN: 1369-7056 [Print] England
PMID16254788 (Publication Type: Journal Article)
Chemical References
  • Alkanesulfonates
  • PPAR alpha
  • PPAR gamma
  • Phenylpropionates
  • tesaglitazar
Topics
  • Alkanesulfonates (chemical synthesis, metabolism, pharmacology, therapeutic use)
  • Animals
  • Clinical Trials as Topic
  • Humans
  • PPAR alpha (agonists)
  • PPAR gamma (agonists)
  • Patents as Topic
  • Phenylpropionates (chemical synthesis, metabolism, pharmacology, therapeutic use)
  • Structure-Activity Relationship

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: